Artemis deficiency is known to result in classical TÀBÀ severe combined immunodeficiency (SCID) in case of Artemis null mutations, or Omenn's syndrome in case of hypomorphic mutations in the Artemis gene. We describe two unrelated patients with a relatively mild clinical TÀBÀ SCID phenotype, caused by different homozygous Artemis splice-site mutations. The splice-site mutations concern either dysfunction of a 5 0 splice-site or an intronic point mutation creating a novel 3 0 splice-site, resulting in mutated Artemis protein with residual activity or low levels of wild type (WT) Artemis transcripts. During the first 10 years of life, the patients suffered from recurrent infections necessitating antibiotic prophylaxis and intravenous immunoglobulins. Both mutations resulted in increased ionizing radiation sensitivity and insufficient variable, diversity and joining (V(D)J) recombination, causing B-lymphopenia and exhaustion of the naive T-cell compartment. The patient with the novel 3 0 splice-site had progressive granulomatous skin lesions, which disappeared after stem cell transplantation (SCT). We showed that an alternative approach to SCT can, in principle, be used in this case; an antisense oligonucleotide (AON) covering the intronic mutation restored WT Artemis transcript levels and non-homologous end-joining pathway activity in the patient fibroblasts.
Introduction
Severe combined immunodeficiency (SCID) is an inherited primary immunodeficiency. Most SCID patients suffer within months after birth from severe opportunistic infections, chronic diarrhea and failure to thrive. Antimicrobial prophylaxis and immunoglobulin (Ig) substitution are mandatory in clinical management, but curative treatment can only be obtained by allogeneic stem cell transplantation (SCT) and, in an experimental setting, gene therapy. [1] [2] [3] Immunologically, SCID is characterized by an absence or dysfunction of T lymphocytes. SCID patients can be divided into two main categories: those with TÀB þ SCID (70%), generally resulting from a T-cell signaling defect and those with TÀBÀ SCID (30%), mostly due to a defect in recombination of the variable (V), diversity (D) and joining (J) gene segments. 4, 5 Differentiation of lymphoid precursors to mature B and T lymphocytes requires the rearrangement and expression of genes encoding the Ig or T-cell receptors. V(D)J gene segments are recombined to form a functional V(D)J exon. V(D)J recombination is initiated by the lymphoid-specific recombination activating gene 1 (RAG1) and 2 (RAG2) proteins. These proteins introduce double strand breaks (DSBs) in the DNA near the recombination signal sequences that flank the V, D and J segments. 6, 7 Subsequently, the DNA DSBs are repaired by the non-homologous end-joining (NHEJ) pathway. The DNA DSBs are recognized by the DNA-dependent protein kinase (DNA-PK) complex, which is composed of the DNA-PK catalytic subunit (DNA-PKcs) and the KU70/KU80 heterodimer that directly binds to the DNA ends. 8 Subsequently, the Artemis protein is phosphorylated by DNA-PKcs and opens the hairpinsealed coding ends. 9, 10 The coding ends are then further processed by inclusion of palindromic (P) nucleotides due to asymmetric hairpin opening, loss of nucleotides due to exonuclease activity and addition of nontemplated (N) nucleotides by terminal deoxynucleotidyl transferase. 11 In the final step, the coding ends are ligated by the DNA ligase IV (LIG4)/XRCC4 complex, in conjunction with XLF (Cernunnos). 12, 13 In approximately 70% of TÀBÀ SCID patients, mutations are found in the RAG1 and RAG2 genes. 14 The majority of the remaining patients show hypersensitivity for ionizing radiation (IR), suggesting a defect in the NHEJ pathway of DNA DSB repair. 15 Mutations in the Artemis, LIG4 and DNA-PKcs genes have been identified in these patients. 14, [16] [17] [18] [19] Furthermore, mutations in the XLF gene have been found in radiosensitive patients with growth retardation, microcephaly and immunodeficiency due to profound T-and B-cell lymphocytopenia. 13 Not all mutations in V(D)J recombination genes give rise to the classical SCID phenotype. Hypomorphic mutations in the RAG1, RAG2 and Artemis genes can result in the Omenn's syndrome. 20, 21 Similar to SCID patients, Omenn's syndrome patients present, in infancy, with viral or fungal pneumonitis, chronic diarrhea and failure to thrive. Unlike classical SCID, patients with Omenn's syndrome have severe erythroderma, increased IgE levels and eosinophilia. 22, 23 Hypomorphic RAG1 and RAG2 mutations have also been reported to cause primary immunodeficiency disease with granulomatous skin lesions. 24 Here, we present two SCID patients with different types of Artemis splicing defects, both leading to an atypical Artemis-SCID phenotype, characterized by a later onset and milder disease course and, in one patient, severe localized granulomatous skin lesions.
Results
Case report patient 1 Patient 1 (ID189) is the second daughter of healthy, consanguineous parents of Turkish descent. She presented at the age of five, with two episodes of pneumonia, of which the last one was caused by Influenza A. Adenotomy was performed due to frequent upper respiratory tract infections. She experienced chickenpox during infancy, with a normal clinical course. The patient was generally in a good clinical condition, with a good psychomotor development and normal growth. The family history revealed one male cousin who had died in Turkey at the age of 15 years from a hematological malignancy. He had been diagnosed with common variable immunodeficiency, suffered from recurrent infections and had been on intravenous immunoglobulin (IVIG) replacement therapy. Another female cousin had been on IVIG therapy for some years as a child, but had apparently grown up to be a healthy adult. Physical examinations showed a healthy girl with no dysmorphic features, no lymphadenopathy or splenomegaly, remarkably small tonsils and diffuse pulmonary wheezing and rhonchus. Antibody responses to pneumococcal polysaccharides and tetanus vaccinations were normal. PCR for Epstein Barr virus (EBV) was positive with incomplete seroconversion (EBV-VCA IgM neg; EBV-VCA IgG pos; anti-EBNA neg). The antibody titers after previous vaccination against mumps, measles and rubella were in the normal range, IgM anti-Varicella was negative, IgG was positive. Antibodies against cytomegalovirus (CMV) and PCR for CMV sequences were negative. A high resolution computed tomography scan showed minimal brochiectasis, with a normal pulmonary function test. On co-trimoxazole prophylaxis, the next 2 years were uneventful, although signs of mild chronic pulmonary inflammation persisted. Because of an increase in respiratory complaints, eventually IVIG was started, which led to a marked clinical improvement. However, at the age of 9 years, she suffered again from frequent respiratory tract infections and increased exercise intolerance. Laboratory tests showed a progressive decrease of B cells and naive T lymphocytes. SCT was performed at 11 years of age, using a matched-unrelated donor and a conditioning regimen containing busulfan, fludarabin and alemtuzumab.
Case report patient 2
This female patient (ID153) of Turkish descent, born from consanguineous parents, presented at the age of 4 years, with a history of recurrent upper and lower respiratory tract infections requiring treatment with oral antibiotics. After 2 years she developed a severe hypogammaglobulinemia and IVIG substitution was initiated. After the start of IVIG, infection episodes became scarce and mild. Notably, although a primary EBV infection was experienced without clinical manifestations, recurrent EBV reactivations, measured by plasma EBV-DNA specific quantitative PCR, could be documented from the age of 7 years onwards. In addition, the patient had an uncomplicated course of chickenpox before the age of 4 years, and spontaneously recovered from Influenza A infection at the age of 9 years. Specific antibodies against Varicella zoster virus and H. influenzae (after vaccination in infancy) could be detected. At the age of 5 years, she developed skin lesions on the back of her left hand, which steadily progressed into multiple isolated and subsequently confluent lesions on the left hand and lower arm (Figure 1 ). Histological analyses showed granulomatous inflammation (reported before 25 ). Despite extensive and repetitive pathological, microbiological and molecular evaluations, no mycobacterial or fungal pathogens or other infectious agents could be detected. Furthermore, multiple episodes of empirical treatment with tuberculostatic agents or intralesional corticosteroid injections did not affect the progressive behavior of the lesions. On the basis of the T-and B-lymphopenia, together with the progressive granulomatous skin lesions, the decision was made to treat the patient with allogeneic SCT. After conditioning with busulfan, cyclophosphamide and ATG (thymoglobulin), a 6/6-allele matched-unrelated cord blood was infused to the patient at the age of 10 years. SCT was considered successful, as all blood myeloid and lymphoid cells were from the donor origin. Functional immune reconstitution was observed, documented by recovery of naive T cells and normal B-cell counts, clearance of reactivated EBV, CMV and adenovirus, and regression of the granulomatous skin lesions (Figure 1 ).
Immunological characteristics
Immunological evaluation in patients 1 and 2 revealed decreased numbers of T cells and B cells, but normal levels of natural killer (NK) cells (Table 1) . Within the Tcell subsets the numbers of memory and activated T cells were normal, whereas the naive (CD45RA þ ) T cells were low. Apparently, the history of both patients regarding vaccination responses and dealing with viral infections indicates that the T cells present are able to support humoral immune responses and to perform cellular immune functions. The serum immunoglobulin levels in patient 1 were normal, except for the decrease in IgG2 and IgG4 levels ( Table 1) . In patient 2, the immunoglobulin levels were normal at 4 years of age, but 2 years later, she developed a severe hypogammaglobulinemia (Table 1) . We analyzed if the B cells could undergo somatic hypermutation (SHM) for affinity maturation of the antigen receptor, by determining the mutation frequency in IgG and IgA transcripts. The overall mutation frequency in patient 1 at 5 years of age was normal, whereas in patient 2, at 8 years of age the mutation frequency was significantly lower than in agematched healthy controls (Figure 2) . In both patients, the pattern of SHM was suggestive for the potential to produce an antigen-selected B-cell receptor. Despite the low numbers of B and T cells, the infectious episodes in the patients were limited, especially after initiation of Artemis splice defects cause atypical SCID H IJspeert et al IVIG, indicating that the immune system is only partially impaired.
Precursor B-cell differentiation block and increased ionizing radiation sensitivity Both patients showed a combined immunodeficiency with reduced numbers of peripheral B lymphocytes and naive T lymphocytes, which is suggestive for a general differentiation defect of cells belonging to the adaptive immune system. Therefore, precursor B-cell differentiation was studied in bone marrow ( clonogenic survival assay was performed to determine whether the patients' fibroblasts, cultured from a skin biopsy were radiosensitive. Fibroblasts from both patients showed increased sensitivity to IR ( Figure 3b ). In contrast, peripheral blood mononuclear cell (PBMC) of patient 2 did not have increased numbers of karyotype abnormalities after low doses of ionizing radiation. Therefore, DSB repair was studied in more detail in patient 2 by counting g-H2AX foci, a DSB marker, at various time points after irradiation. The g-H2AX foci disappeared with delayed kinetics in patient 2 and Artemis-deficient fibroblasts ( Figure 3c ). This resulted in 15% residual foci after 72 h, suggesting that a comparable level of unrepairable DSBs remained in patient 2 fibroblasts and in Artemis-deficient cells. These observations were indicative for a defect in DSB repair by NHEJ.
Hypomorphic mutations in Artemis
Artemis is the first candidate gene for NHEJ defects. Therefore, the coding exons and splice-sites of the Artemis gene were sequenced. Patient 1 had a homozygous mutation in the 5 0 splice-site of exon 6 (c.464 þ 1G4A) (Figure 4a ). The same mutation was recently described in a patient with an atypical Artemis deficiency with chronic inflammatory bowel disease. 26 This splice-site mutation leads to alternative splicing, yielding two aberrant Artemis transcripts. In the first transcript (Artemis ex5-ex7), exon 6 is skipped, leading to an in-frame deletion of 34 amino acids of the b-Lact domain (p.M121_R155delinsI). The b-Lact domain is essential for Artemis activity, as mutants, lacking parts of the b-Lact domain, could not complement the Artemis defect. 27 In the second transcript (Artemis ex6 þ 18nt), a cryptic 5 0 splice-site, 18 nucleotides downstream of exon 6, was used resulting in the in-frame insertion of six amino acids (p.R155_V156insYWGSYR) (Figure 4a ). The 6 amino acids are inserted exactly between the b-Lact and the b-CASP domains, leaving the b-Lact domain intact. Rohr et al. 26 showed that the Artemis protein carrying this insertion of 6 amino acids retained residual activity In patient 2, no mutations were found in the coding exons and splice-sites of the Artemis gene. However, polymorphic short-tandem repeat markers up-and downstream of the Artemis gene showed that this locus was homozygous in the patient. As the patient's parents are consanguineous, Artemis was still considered a candidate gene. Therefore Artemis transcripts were sequenced. This revealed a 190-bp insertion (cryptic Table 2a . Relative Artemis expression measured in fibroblasts of control (C5RO), patient 1 or 2, an Artemis-deficient patient (Artemis-5) 27 lacking exon 1 till 3, a patient expressing mutant Artemis (Artemis-8) 27 and a RAG-deficient patient (RAG-SCID-12). WT Artemis transcripts were not expressed in fibroblasts of patient 1. For detection of WT Artemis transcripts in patient 1, a forward primer overlapping the exon 6-7 border (Artemis ex6ex7 F) in combination with a reverse primer in exon 8 (Artemis ex8R) and the probe TR Artemis ex7ex8 (b). WT Artemis transcripts were expressed at low level in fibroblasts of patient 2 (c). T, B and NK cells from patient 1 only expressed patient-specific Artemis transcripts (d). In patient 2, the WT Artemis transcripts expression was higher in T, B and NK cells compared with fibroblasts (e). The expression levels of the patient-specific Artemis transcripts were slightly higher in mature B cells (CD19 þ IgD þ IgM þ ) compared with precursor B cells (CD19 þ IgDÀ) in patient 1 (f), but in patient 2, the WT Artemis expression in mature B cells was much higher compared with precursor B cells (g). exon) between exons 11 and 12. Genomic sequence alignment showed that the inserted cryptic exon was part of Artemis intron 11, located B2.0 kb downstream of exon 11 (Figure 4a ). Sequence analysis of this part of the intron and the flanking regions in genomic DNA revealed a homozygous nucleotide substitution (c.972 þ 1997G4C), which introduced a new 3 0 splicesite consensus sequence. Besides this newly formed 3 0 splice-site, a pre-existing cryptic 5 0 splice-site was used. At the protein level, a stretch of 61 amino acids was inserted after glutamate 324, followed by a stop codon (p.
cells
To determine the levels of WT and patient-specific aberrant transcripts in different cell types, real time quantitative (RQ) PCR was performed. The location and sequences of the primers and probes used to measure the different transcripts are indicated in Figure 4a and Table 2 . Fibroblasts of patient 1 only expressed patientspecific alternative Artemis transcripts, but no WT Artemis transcripts (Figure 4b) . None of the patientspecific Artemis transcripts were expressed in control fibroblasts or in fibroblasts of Artemis-deficient or RAGdeficient SCID patients. Fibroblasts of patient 2 expressed both patient-specific Artemis transcripts (Artemis ex11 þ 190nt) and WT Artemis transcripts, although WT expression was much lower (4300 fold decrease) than in control fibroblasts (Figure 4c ). The respective absence or strong decrease in WT Artemis transcripts in patient 1 and 2 explains the sensitivity to IR of the fibroblasts. WT Artemis expression was also absent in sorted T, B and NK cells of patient 1 (Figure 4d ).
The expression of WT Artemis in the sorted lymphocyte subsets of patient 2 was only 10-fold decreased compared with control subsets (Figure 4e ). This decrease was much less than the 4300-fold decrease of WT Artemis transcripts in fibroblasts, and could explain why the fibroblasts of patient 2 were sensitive for IR while the PBMCs of patient 2 were not. This difference in WT Artemis expression could not be explained by reversion mutations in T, B and NK cells, as these were excluded by sequence analysis of sorted fractions (data not shown). The 10-fold decrease of WT Artemis in PBMCs in patient 2 was unexpected, as precursor B cells in BM had a clear V(D)J recombination defect due to improper or insufficient NHEJ activity. Therefore, precursor B cells (pre-B-I, pre-B-II and immature B cells) and mature B cells were sorted from BM to determine Artemis transcript levels. The expression level of WT Artemis transcripts in precursor B cells was approximately 40-fold lower than in mature B cells derived from patient 2 (Figure 4g ). The expression levels of both mutant Artemis transcripts in precursor B cells in patient 1 were only slightly lower compared with mature B cells (Figure 4f ). In summary, the difference in sensitivity to IR between fibroblasts and PBMC can be explained by the differential expression of Artemis transcripts in fibroblasts versus lymphocyte populations and differences in expression in B-cell subsets of various differentiation stages.
Effect of the Artemis splice-site mutations on V(D)J recombination
The two patients had different types of Artemis splice-site mutations. Patient 1 had a homozygous splice-site mutation resulting in expression of mutant Artemis protein with residual activity, whereas patient 2 had a mutation causing severely reduced expression of WT Artemis transcripts. To understand the effects of the different hypomorphic Artemis mutations on its function, we studied Artemis-related processes during B-cell differentiation. Artemis is involved in V(D)J recombination, which takes place during precursor B-cell differentiation. Both mutations had effect on V(D)J recombination, given the block in precursor B-cell differentiation in BM (Figure 3a) . Therefore, we studied V(D)J recombination in more detail by analyzing the coding joints of incomplete IGH gene rearrangements (that is, DH-JH) in DNA isolated from BM mononuclear cells.
Both Artemisand DNA-PKcs-deficient patients have a defect in DNA hairpin opening and show increased P-nucleotides in DH-JH junctions (Table 3) . 18, 19, 27 In coding joints of both patients, the average number of palindromic (P-) nucleotides per junction was significantly increased to 1.2 in patient 1, and 2.0 in patient 2 compared with healthy controls (0.3 Artemis splice defects cause atypical SCID H IJspeert et al P-nucleotides per junction) ( Table 3 ). These long stretches of P-nucleotide resulted in significantly less deletions compared with controls. The number of non-templated (N-) nucleotides was not significantly different from controls. These results show that mutant Artemis with residual activity in patient 1 or low levels of WT Artemis in patient 2 resulted in defective hairpin opening.
Effect of the Artemis mutations on CSR
In mature B cells, class switch recombination (CSR) allows previously rearranged Ig heavy-chain V domains to be expressed in association with a different constant (C) region, leading to production of different isotypes. 29 Artemis has recently been shown to be involved in CSR. 23 Switch (S) junctions resulting from in vivo (CSR) events, were cloned and sequenced from B cells of patient 1 and 2. Unique Sm-Sa1 sequences, representing independent CSR events, were subsequently compared with Sm and Sa junctions (n ¼ 154) from healthy adult controls. 30, 31 Previously described Artemis-deficient patients showed a strong dependence on long microhomologies and a complete lack of 'direct end-joining'. 23 The average length of microhomology, defined as successive nucleotides that were shared by both the Sm and Sa regions at the CSR junctions, was not significantly different from control in patient 1 (3.8 ± 5.2 bp versus 1.8±3.2 bp in controls) and in patient 2 (2.0±2.7 bp versus 1.8 ± 3.2 bp in controls). Furthermore, the pattern of Sm-Sa junctions was indistinguishable from that in controls (Table 4 ). In summary, expression of mutated Artemis protein with residual enzymatic activity or reduced level of WT Artemis had no impact on CSR.
In vitro restoration of the Artemis splice defect by antisense oligonucleotide (AON) exon skipping The defect in patient 2 was caused by a rare intronic mutation that creates a new splice-site leading to exonisation of 190 nucleotides of intronic sequence. We attempted to correct this defect by skipping this cryptic exon. For this purpose, we used antisense oligonucleotides (AONs) to modulate splicing by hiding specific sites essential for exon inclusion from the splicing machinery, without modifying the genome. 32 The AONs used to modulate splicing are different from the oligonucleotides that are used to achieve downregulation of transcripts. The AONs should not activate RNase H, which would degrade the pre-mRNA, and should be able to compete with splicing factors for access to the pre-mRNA. We have applied an AON with 2 0 -O-methyl ribose groups and a full-length phosphorothioate backbone. This AON is RNase H inactive and has a higher affinity for the target sequence than the 2 0 -deoxy counterpart. For patient 2, an AON covering the newly formed 3 0 splice-site in intron 11 of the Artemis gene was designed (Figure 5a ). Fibroblasts of patient 2 and a healthy control were transfected with a 5 0 fluoresceinlabeled AON. After 24 and 48 h, WT and mutant (Artemis ex11 þ 190nt) Artemis transcript levels were The switch junctions from Artemis-deficient patients were compared with those from age matched controls (1-6 years of age), whereas the switch junctions from patient 1 and 2 were compared with adult controls. *Po0.05; ***Po0.001. Abbreviations: DH(del), average number of nucleotides deleted from the 3 0 end of the DH gene segment per coding joint given as a negative value; DNA-PKcs, DNA-dependent protein kinase catalytic subunit; JH(del) average number of nucleotides deleted from the 5 0 end of the JH gene segment per coding joint given as a negative value; N, non-templated; P, palindromic; Total del, average of total number of deleted nucleotides per coding junction. Values represent average numbers of nucleotide per junctions. Statistical analysis was performed using unpaired T-test. **Po0.01; ***Po0.001.
Artemis splice defects cause atypical SCID H IJspeert et al measured by RQ-PCR. The levels of WT Artemis transcripts in patient 2 were already restored to normal levels within 24 h after transfection (Figure 5b ). In addition, mutant Artemis expression was approximately 10-fold decreased. No effects of AON transfection were seen on Artemis expression levels in control fibroblasts. Moreover, in the clonogenic survival assay, we demonstrated that AON treatment also partially suppressed the sensitivity to IR in the patient fibroblasts (Figure 5c ). In conclusion, Artemis splice-site defect could be restored by AON mediated cryptic exon skipping.
Discussion
In this study, we described two unrelated girls suffering from recurrent infections during the first 10 years of their lives. The infectious problems associated with decreased B cell and naive T-cell counts in combination with reduced serum Ig isotype and IgG subclass levels necessitated IVIG therapy. They had normal psychomotor development and growth. Patient 2 suffered from severe localized granulomatous skin lesions. The clinical presentation of both patients was caused by two different types of Artemis splice mutations resulting in residual enzymatic activity in one patient and reduced level of WT activity in the other patient. Artemis deficiency normally causes TÀBÀ SCID with opportunistic infections already during the first months of life. Although both patients had an Artemis defect, the infectious episodes were limited with a relatively mild course, especially after initiation of IVIG. Apparently, the T cells present were able to induce cellular immune responses and to support humoral immunity. However, due to a low number of B cells, naive T cells and a potentially limited Ig and T-cell receptor repertoire, clonal selection will be less optimal, giving rise to dysregulation in the immune system. This immune dysregulation might underlie the granulomatous skin lesions in patient 2.
Immunodeficiency disease with granulomas has been described previously in patients with hypomorphic mutations in the RAG1 or RAG2 genes. 24, 33 Similar to patient 2, repeated tests revealed no micro-organisms in the granulomas of these RAG-mutated patients, suggesting that the granulomas were secondary to the impaired immune regulation. The granulomatous skin lesions largely resolved after transplantation and reconstitution of the donor immune system in patient 2, comparable to the patients with hypomorphic RAG mutations. 24 Apparently, V(D)J recombination defects with residual recombination activity can give rise to a variety of atypical clinical presentations. 33 One (c.464 þ 1G4A) of the two Artemis mutations was previously identified in a patient with late onset immunodeficiency and inflammatory bowel disease that presented at the age of 9 months. 26 The same Artemis genotype resulted in a different clinical phenotype; this might be due to age at the first encounter of infections, genetic background (for example, modifier genes or epigenetic factors) or environmental factors. 33 The second mutation (c.972 þ 1997G4C) is a unique homozygous mutation in intron 11 of the Artemis gene resulting in exonization of 190 nucleotides from an intronic sequence in Artemis transcripts. The mutation corresponds to a nucleotide substitution at position 279 of an Alu consensus sequence. 34 Interestingly, it has been shown that mutating this specific guanine nucleotide to any other nucleotide, as is the case in patient 2, results in exonization of the Alu sequence. 34 The Artemis gene has a higher transposable element content (45%) than the average of the human genome (37%). 35 The most abundant Artemis splice defects cause atypical SCID H IJspeert et al transposable elements found in Artemis are Alu shortinterspersed elements (23% of total gene sequence), making Artemis prone to exonization of Alu elements in mRNA during splicing. As expected from the V(D)J recombination defect, the expression level of mutant and WT Artemis transcripts in patient 1 and 2 was strongly reduced in precursor B cells and fibroblasts. However, mature B cells had only mildly reduced levels of Artemis transcripts. The different splicing patterns between fibroblasts, precursor B cells, mature B cells, T cells and NK cells might be caused by cell type and tissue-specific patterns of alternative splicing. 36, 37 However, differences in the various B-cell subsets might also reflect positive selection of a limited number of precursor B-cell clones that had a higher Artemis expression and were therefore able to generate a functional B-cell receptor and differentiate into mature B cells.
To dissect the functional impact of the hypomorphic Artemis mutations, we studied Artemis-related processes during B-cell development. In precursor B cells the reduced Artemis activity or low level of WT Artemis protein resulted in inefficient V(D)J recombination. In mature B cells, Artemis is involved in CSR. 23, 38 Artemisdeficiency results in CSR characterized by strong dependence of long microhomologies in the S junctions and a complete lack of ''direct end-joining''. We showed that reduced levels of WT Artemis and residual Artemis activity resulted in normal S-junction formation.
Current treatments for SCID patients include SCT 39 and gene therapy for some conditions. 40 However, SCT is still associated with significant treatment-related morbidity and mortality, especially when material from unrelated and HLA-mismatched donors is used. 41 Gene therapy is currently limited by technical difficulties and the risk of side effects. 42 New approaches for treatment of primary immunodeficiencies have been described, including the use of antisense morpholino oligonucleotides. 43 In this study, we used 2 0 -O-methyl-modified AONs to restore the expression of WT Artemis transcripts, without modifying the genome. AON treatment has also been successfully used in gene correction therapy to restore the reading frame in Duchenne muscular dystrophy patients. 44 Our in vitro results showed the potential for AON treatment as therapeutical approach for patients with specific splice defects.
In conclusion, patients with an Artemis defect can present as an atypical SCID with granulomatous skin lesions in the absence of life-threatening infections. Therefore, an NHEJ defect needs also to be considered in patients having reduced number of naive T cells and B cells in the circulation, who presented with milder clinical symptoms than classical TÀBÀ SCID. Furthermore, this study illustrates that AON treatment is a promising approach to treat patients with primary immunodeficiencies and other diseases caused by intronic splice-site mutations.
Materials and methods
Cell samples and flow cytometric immunophenotyping Peripheral blood, BM and a skin biopsy were obtained with informed consent and according to the guidelines of the local Medical Ethics Committees. Flow cytometric analysis of peripheral blood and BM was performed as previously described. 16, 18, 45 Cell lines and tissue culture Primary fibroblasts were cultured from a skin biopsy of patient 1 and 2. Furthermore, fibroblasts from controls (C5RO and VH10), Artemis-deficient patients (Artemis-5 and Artemis-6; both having genomic deletions of exon 1-3 27 ), a patient with mutant Artemis (Artemis-8 (c.1391_1395delGAATC)) and a RAG-deficient patient (RAG-SCID12) (c.1782C4A)) were used. Fibroblasts were cultured in Dulbecco's modified Eagle medium (BioWhittaker, Walkersville, MD, USA), supplemented with 10% fetal calf serum, penicillin (100 U/ml) and streptomycin (100 mg/ml).
Radiation sensitivity assays
Clonogenic survival assay and the X-ray-induced gH2AX foci assay were performed as previously described. 18, 19, 27 Sequencing and STR marker analysis Sequence analysis of genes involved in V(D)J recombination and NHEJ was performed by PCR analysis (for RAG1 (NCBI M29474), RAG2 (NCBI M94633), Artemis/ DCLRE1C (NCBI NM 001033855), XLF/NHEJ1 (NCBI AJ972687) and LIG4 (NCBI X83441) or RT-PCR analysis (for Artemis/DCLRE1C) of the coding regions with the TaqGold amplification system (Applied Biosystems, Foster City, CA, USA), followed by direct sequencing. Primer sequences are available upon request. STR marker analysis was performed as previously described. 19 Real-time quantitative PCR (RQ-PCR) Primers and probe (Table 2) were designed to amplify WT or patient-specific Artemis transcripts using Taqmanbased RQ-PCR. The RQ-PCR was performed on the ABIPRISM 7700 sequence detection system (Applied Biosystems), as described previously. 46 Analysis of coding joints and SHM DH-JH junctions were analyzed as previously described. 19, 27 SHM was studied in VH3-Ca, VH4-Ca, VH3-Cg and VH4-Cg fragments, amplified from PBMC cDNA and cloned into pGEM-T easy vector (Promega, Madison, WI, USA). IMGT nomenclature (http://imgt.cines.fr/) was used to assign the V, D and J segments, and to identify somatic mutations. 47 The mutation frequency was determined for the VH gene segment of each transcript.
Characterization of switch recombination junctions Genomic DNA was purified from PBMCs using standard methods. The amplification of Sm-Sa fragments from in vivo S cells was performed, as described previously, 30, 48 except that a modified version of Taq polymerase (Go Taq, Promega) was used in the PCR reactions. With this modification, a 2-4-fold increase in sensitivity was achieved. The PCR amplified S fragments were gel purified (Qiagen, Hilden, Germany), cloned into a modified version of the pGEM-5zf ( þ ) vector and sequenced by an automated fluorescent sequencer in Macrogen (Seoul, Korea). The S recombination breakpoints were determined by aligning the S fragment sequences with the corresponding reference sequences (Sm, X54713; Sa1, L19121; Sa2, AF030305), as described previously. 30, 49 
